Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

Related Articles

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

7 months ago

Is Microsoft's $50 Billion Global South AI Bet a Game Changer

7 months ago

Is Highmark's Digital Therapeutics Coverage a Game Changer for Investors

5 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

5 months ago

Category

You may also like

Stock News•3 weeks ago

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Cue Biopharma was initiated with a Buy rating after CUE-221's phase 2 trial in chronic spontaneous urticaria showed 54% of patients achieving complete hive resolution at 12 weeks versus XOLAIR. Upcomi...

CUE

Share

Stock News•1 months ago

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

UCB agreed with the U.S. government to lower medicine costs and boost domestic manufacturing, per a PRNewswire release. The deal could affect pricing and U.S.

Share

Stock News•2 months ago

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Argenx agreed to buy Forte Biosciences in an all-cash deal, gaining a promising autoimmune drug candidate to bolster its pipeline.

FBRX

Share